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HospitalsAbstract Adverse Drug Reactions (ADRs) are scantly reported with poor contribution by health-
care professionals worldwide and in particular in developing countries. The aim of this study was to
assess the knowledge and awareness of adverse drug reactions (ADRs) reporting and pharmacovig-
ilance system among healthcare professionals in Al-Madinah Al-Munawwarah hospitals, Kingdom
of Saudi Arabia. A questionnaire was designed addressing; awareness of ADRs, knowledge of phar-
macovigilance system, availability of ADRs reporting system, patient counseling about ADRs and
documentation of ADRs. The questionnaire was distributed to randomly selected healthcare pro-
fessionals (n= 585) such as physicians, pharmacists, nurses and pharmacists’ technicians of hospi-
tals. Completed questionnaires were collected and data were analyzed. Data were expressed in
number as well as percentage. Of the 585 questionnaires circulated, a total of 384 healthcare pro-
fessionals responded. Healthcare professional categories involved in the study were 148 physicians,
37 pharmacists, 158 nurses and 41 pharmacist technicians. The percent of the respondents who
accepted to enroll in the study was 65.64%. Most of the respondents were unable to correctly deﬁne
the pharmacovigilance term, but they were aware of ADRs. The awareness among healthcare
professionals of the national pharmacovigilance system was 39.6%. Pharmacists had a good
Awareness of ADRs and Pharmacovigilance in Saudi Arabia Hospitals 155knowledge of pharmacovigilance and ADRs terminology and showed a more positive attitude to
report ADRs. A greater number of the healthcare professionals were aware of ADRs reporting,
but practically it is not implemented in hospitals. Most hospitals had follow-up documentation sys-
tems, but did not include ADRs reporting. There was no distinct pharmacovigilance system in
place. Our study has demonstrated a lack of knowledge and awareness of pharmacovigilance and
ADRs reporting among healthcare professionals in hospitals. The poor knowledge of ADRs report-
ing emphasized the urgent need to implement the appropriate strategies to improve the awareness of
pharmacovigilance practices and ADRs reporting in Al-Madinah Al-Munawwarah hospitals.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Medications have caused and will continue to cause harm to a
number of people’s lives alongside many beneﬁts. Adverse
Drug Reactions (ADRs) are a major problem and are one of
the leading causes of mortality and morbidity (Lazarou
et al., 1998; Classen et al., 1997). Adverse drug reaction
(ADR) is deﬁned according to WHO (2002a) as any response
to a drug which is noxious and unintended and occurs at doses
normally used in man for prophylaxis, diagnosis or therapy of
disease or the modiﬁcation of physiological function.
ADRs are associated with prolonged length of hospital stay,
increased economic burden and increased death. Many studies
have reported that ADRs were responsible for large numbers of
hospital admissions (Lazarou et al., 1998; Jick, 1984;
Pirmohamed et al., 2004; Ahmed, 1997). In the United States,
more than 100,000 deaths are attributed annually to serious
adverse drug reactions (Lazarou et al., 1998). In the UK, about
6.5% of all admissions to hospitals are due to an ADR, and the
overall fatality was 0.15% (Pirmohamed et al., 2004). A pro-
spective study by Ahmed (1997) demonstrated that drug-
related problems report in Saudi Arabia showed that the mor-
tality rate associated with ADRs in provincial hospitals was
found to be 3.8% from the overall deaths in the general prac-
tice. There are differences among countries and regions within
countries in the occurrence of drug-related problems. This may
be due to differences in diseases, prescribing practices, genetics,
diet habits and use of herbal remedies which may pose speciﬁc
toxic problems. Under-reporting of adverse drug reactions
(ADRs) is very common. It has been estimated that only 6–
10% of all the ADRs are reported (Feely et al., 1990).
There is a considerable increase in awareness about the
issues related to drug safety among healthcare providers,
healthcare institutions and the public. The term pharmacovig-
ilance has evolved to recognize the importance for monitoring
and improving the safe use of medicines.
World Health Organization (WHO, 2002b) deﬁnes pharma-
covigilance as ‘‘the science and activities relating to the detec-
tion, evaluation, understanding, and prevention of adverse
reactions tomedicines or any othermedicine-related problems’’.
Uppsala Monitoring Centre (UMC), located in Uppsala, Swe-
den, is the ﬁeld name for theWorldHealthOrganizationCollab-
orating Centre for International Drug Monitoring. The UMC
works by collecting, assessing and communicating information
frommember countries’ national programs in regard to the ben-
eﬁts, harm, effectiveness and risks of drugs.
A national pharmacovigilance center was established by
Saudi Food and Drug Authority (SFDA) in March 2009 andit is one member of the WHO Collaborating Centre in Upp-
sala, Sweden. The national pharmacovigilance system is the
main way to collect information about ADRs occurrences in
both the hospital and community settings. The effectiveness
and success of any pharmacovigilance system depend highly
on the participation of all healthcare professionals and the
degree of co-operation and communication between the prac-
titioners and pharmacovigilance center.
There is a lack of studies that address the knowledge, atti-
tudes and perception of healthcare professionals toward the
pharmacovigilance system and ADRs reporting, which is car-
ried out in this country. In a country like Saudi Arabia with
multiethnic groups and a high rate of use of herbal and com-
plementary medicine, practitioners can play a major role in
detecting and reporting ADRs associated with the use of such
products. It is important to conduct comprehensive studies to
explore and evaluate the roles of healthcare professionals and
their contributions in the pharmacovigilance activities. The
aim of the present study was to assess the knowledge and
awareness of ADRs reporting and pharmacovigilance system
among the healthcare professionals in Al-Madinah Al-Mun-
awwarah Hospitals, Kingdom of Saudi Arabia.2. Materials and methods
2.1. Design of the questionnaire
A questionnaire was developed to obtain information on the
knowledge and awareness of pharmacovigilance and adverse
drug reactions reporting, availability ofADRs reporting systems,
patient counseling about ADRs and documentation of ADRs.
2.2. Hospitals visits
The healthcare professionals (physicians, pharmacists, nurses
and pharmacist’ technicians) of some 9 hospitals were pro-
vided with a copy of the questionnaire after explanation of
the objectives of the study. The healthcare professionals were
provided with enough time to ﬁll the questionnaire. The ques-
tionnaire was explained to each practitioner in order to pre-
clude any potential misunderstanding, and also the name of
the participant was made optional.
2.3. Healthcare professionals participation
A total 585 questionnaires were circulated, and a total of 384
healthcare professionals responded to ﬁll the questionnaire
Table 1 Total number of healthcare professional respondents
in hospitals.
Healthcare professional
Respondents
Total
(585)
Response
Accepted (384) Rejected (201)
Pharmacists 52 37 15
Pharmacists’ Technicians 68 41 27
Physicians 209 148 61
Nurses 253 158 95
Table 2 Total number of healthcare professional respondents’
nationalities in hospitals.
Nationality Total (585) Accepted (384) Rejected (201)
Egypt 159 105 54
Saudi 181 107 74
Sudan 39 32 7
Syrian 27 17 10
Philippine 173 117 56
Jordon 5 5 0
Pakistan 1 1 0
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148 physicians, 37 pharmacists, 41 pharmacist technicians
and 158 nurses. A total of 201 of the healthcare professionals
refused to participate in the study. Table 2 shows the respon-
dents’ nationalities from different hospitals visited. The ques-
tionnaire consisted of information about familiarity with the
ADRs reporting and pharmacovigilance system, attitude
toward ADRs reporting and patient counseling about ADRs
and documentation of ADRs.
2.4. Collection of questionnaires and analysis of data
Complete questionnaires were collected from each participant
in each hospital to evaluate the awareness of pharmacovigi-
lance knowledge and ADRs reporting among healthcareFigure 1 Awareness of the healthcare professiprofessionals. Data were analyzed and presented as a percent
(%) of the respondents. In case of unanswered questions, a
participant was excluded from the study.
3. Results
A total 384 healthcare professionals participated in the study
and the overall percent of the respondents who accepted to
enroll in the study was 65.64%. The major reasons for non-
participation were being too busy and/or unwilling to partici-
pate, too busy or fear. Healthcare professionals to participate
in the study were 148 physicians, 37 pharmacists, 41 pharma-
cist technicians and 158 nurses. A total of 201 of the healthcare
professionals refused to participate in the study.
3.1. Awareness of the healthcare professionals of
pharmacovigilance system
The healthcare professionals (physicians, pharmacists, nurses
and pharmacist technicians) were asked about their knowledge
of the pharmacovigilance in KSA. Most of the practitioners
were unfamiliar with the availability of national pharmacovig-
ilance system in KSA. The total percent of the respondent’s
knowledge of national pharmacovigilance system in KSA
was 39.6% (Fig. 1). The highest percent of the awareness of
pharmacovigilance system was among the pharmacists
(70.27%), pharmacists’ technicians (61%), physicians
(39.2%), and nurses were 27.2% (Fig. 2). The awareness of
the healthcare professionals of pharmacovigilance by national-
ity distribution is presented in Fig. 3. This ﬁgure shows that the
number of Saudi nationality was the highest, followed by
Sudanese, Egyptian, Syrian and Philippines. One of the limits
of this interpretation was the small number of the Saudi and
Sudanese participated in the study.
3.2. Availability of a pharmacovigilance system in hospitals
The healthcare professionals were then asked about the
availability of pharmacovigilance system in their hospitals,onals of national pharmacovigilance system.
Figure 3 Awareness of respondents of the healthcare professionals of pharmacovigilance system by nationalities.
Figure 2 Awareness of the different groups of healthcare professionals of national pharmacovigilance system.
Awareness of ADRs and Pharmacovigilance in Saudi Arabia Hospitals 157the doctors had a high score followed by nurses, and then
pharmacists. The response of the participants about the avail-
ability of pharmacovigilance system at their hospitals is shown
in Fig. 4. It was observed that there was no electronic reporting
system in all hospitals visited, which affects the availability and
sharing of pharmacovigilance information among the different
hospital departments (Fig. 5).
3.3. Awareness of adverse drug reactions (ADRs) reporting
All respondents of healthcare professionals had a positive
awareness for adverse drug reactions (ADRs) reporting.
Fig. 6 shows that a higher number of the healthcare profes-
sionals were aware of ADRs reporting, but practically it is
not applied in the visited hospitals.3.4. Frequency of encountering ADRs
The healthcare professionals were asked about the frequency
of encountering ADRs during their daily work in hospitals.
Fig. 7 shows that physicians encountered ADRs occasionally,
while pharmacists’ technicians and nurses rarely encountered
ADRs. Some pharmacists answered that they encountered
ADRs occasionally, while others they encountered rarely
depending on the hospital and the environment of practice.
3.5. Patient counseling about ADRs by healthcare professionals
Effective communication between healthcare professionals and
patients is one of the most important elements for reducing
ADRS and improving health outcomes. Therefore, healthcare
Figure 4 Availability of a pharmacovigilance system in hospitals.
Figure 5 Availability of an electronic pharmacovigilance reporting system in hospitals.
Figure 6 Awareness of the healthcare professionals of adverse drug reactions (ADRs) reporting.
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Figure 7 Frequency of encountering of ADRs in Hospitals.
Figure 8 Counseling of patients by healthcare professionals about ADRs.
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about ADRs. Fig. 8 demonstrates that doctors had the highest
percent (82.4%) among the other healthcare professional
groups in counseling patients about ADRs. Around 75.7%
of pharmacists and 73.4% of nurses were willing to counsel
patients about ADRS.
3.6. Follow-up and documentation of ADRs in hospitals
Follow-up and documentation is the cornerstone of the phar-
macovigilance system in any hospital. A percent of 47.7% of
physicians and 50.6% of nurses were aware of follow-up and
documentation of ADRs in the visited hospitals (Fig. 9).4. Discussion
Adverse drug reactions (ADRs) are one of the most serious
health problems, and are one of the leading causes of mortality
and morbidity (Pirmohamed et al., 2004; Ernst and Grizzle,
2001). There are differences among countries in the occurrenceof drug-related problems; this may be due to differences in dis-
eases, prescribing practices, diet, traditions of the people and
the use of herbal remedies which may pose speciﬁc toxicolog-
ical problems. Pharmacovigilance has grown in importance
in recent years, and good pharmacovigilance systems will iden-
tify the risks of drug-related problems so that harm can be
avoided. Pharmacovigilance deals with detection, assessment,
understanding and prevention of adverse effects or any other
drug related problems.
In a country like Saudi Arabia withmultiethnic groups and a
high rate of use of herbal and complementary medicine, practi-
tioners can play a major role in detecting and reporting ADRs
associated with the use of such products. It is important to con-
duct comprehensive studies to explore and evaluate the roles of
healthcare professionals and contributions in the pharmacovig-
ilance system activities. Despite the Saudi national pharmaco-
vigilance center that regularly publishes an ADR bulletin, and
information pertaining to ADRs is stored in a national ADRs
database, there is a lack of studies that address the knowledge
and awareness of healthcare professionals about the pharmaco-
vigilance system and ADRs reporting in this country. The pres-
Figure 9 Follow-up and documentation of ADRs.
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healthcare professionals regarding pharmacovigilance and
ADRs reporting. It was observed that the awareness of the
availability of national pharmacovigilance system among
healthcare professionals was 39.6%. Interestingly, pharmacists
were themost knowledgeable group (70.27%) about pharmaco-
vigilance and ADRs reporting, despite the absence of distinct
pharmacovigilance systems or reporting systems in most hospi-
tals. The ﬁndings in our study were reasonably similar to the
observations made in both developing and developed countries.
In China 71% of the healthcare professionals did not have
knowledge of the reporting procedure (Aziz et al., 2007). In
Malaysia, about 40% of the respondents were not aware of
the existence of the national reporting system (Li et al., 2004).
In the European Union (EU), many healthcare professionals
did not know how to report an ADR (Belton, 1997).
The healthcare professionals were asked about the avail-
ability of pharmacovigilance system at their hospitals, the
majority of participants answered that there was no pharmaco-
vigilance system in hospitals. It was noted that healthcare pro-
fessionals (physicians, pharmacists, nurses and pharmacist
technicians) working in hospitals have insufﬁcient knowledge
of pharmacovigilance practices. The main reasons for under-
reporting of ADRs are lack of time, poor knowledge on the
reporting mechanisms, unfamiliarity with the existence of
national pharmacovigilance system, belief that the ADR was
already well known, doubt about the importance of the ADRs
reporting and fear to report ADRs (Lee and Thomas, 2003;
Herdeiro et al., 2005). Al-Hazmi and Naylor (2013) reported
that only 18% of community pharmacists were aware of the
ADR system and 56% of the respondents were not aware of
the existence of the Saudi National Pharmacovigilance center.
Bawazir (2006) also reported that the majority of community
pharmacists surveyed (86.8%) were not aware of the ADRs
reporting program in Saudi Arabia and only twenty-nine per-
cent of pharmacists were aware that pharmacists in Saudi Ara-
bia could report an ADR to the Ministry of Health (MOH). A
survey study in France showed that the majority of medical
residents had minimal knowledge regarding pharmacovigi-
lance (Graille et al., 1994). Another study from Italy reportedthat doctors had little information regarding ADRs and ADR
reporting systems (Cosentino et al., 1997). In the UK, where
pharmacovigilance programs are well established, there is a
high level of under-reporting is documented (Belton et al.,
1995). Healthcare professionals should consider adverse drug
reactions (ADRs) reporting as an obligation and should be
aware of the existing pharmacovigilance mechanisms. The re-
enforcement of pharmacovigilance systems in hospitals should
be a priority basis for the success of the pharmacovigilance
programs and the better clinical management of the patients.
5. Conclusions
The present study pointed out to the lack of the knowledge
and awareness among healthcare professionals of pharmaco-
vigilance system and ADRs reporting systems in hospitals.
The doctors, pharmacists and nurses have a great responsibil-
ity in reporting ADRs and strengthening the pharmacovigi-
lance mechanisms. Our ﬁndings also provide the healthcare
policy makers and health authorities with base line data that
can be used in the future evaluation or re-enforcement plans
and educational initiatives for improving the pharmacovigi-
lance practices and ADRs reporting in hospitals.
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